Fate Therapeutics (FATE) Non-Current Deffered Revenue (2012 - 2022)

Fate Therapeutics (FATE) has 11 years of Non-Current Deffered Revenue data on file, last reported at $12.4 million in Q3 2022.

• Quarterly Non-Current Deffered Revenue fell 61.9% year-over-year to $12.4 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $12.4 million (down 61.9% YoY) and the FY2021 annual result came in at $27.1 million, down 41.06% from the prior year.
• Non-Current Deffered Revenue slipped to $12.4 million in Q3 2022, from $17.7 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $54.7 million in Q2 2020 to a low of $198000.0 in Q1 2018.
• A 5-year average of $20.2 million and a median of $12.4 million in 2022 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue tumbled 91.4% — and 2019, when it jumped 3122.22%.
• Tracing FATE's Non-Current Deffered Revenue over 5 years: stood at $7.5 million in 2018, then slumped by 49.67% to $3.8 million in 2019, then jumped by 1119.1% to $46.0 million in 2020, then tumbled by 41.06% to $27.1 million in 2021, then slumped by 54.26% to $12.4 million in 2022.
• The last three Non-Current Deffered Revenue figures came in at $12.4 million (Q3 2022), $17.7 million (Q2 2022), and $22.5 million (Q1 2022), per Business Quant data.